News

Eisai’s E6201 is a dual-targeted FLT3 and MEK inhibitor, which has completed a PhaseI clinical trial showing preliminary antitumor activity and an acceptable safety profile. Building on a

The deal grants Merz an exclusive North American license, with certain additional international rights, for the development and commercialization of BBI-3000, to treat skin conditions known to be

Under the deal, AcipHex Sprinkle will be distributed by FSC Laboratories and promoted by its subsidiary, FSC Pediatrics, to pediatric primary care-focused practitioners across the US. FSC Pediatrics

The data demonstrate that patients who continued Gattex treatment beyond two years achieved clinically meaningful reductions in parenteral support requirements, including volume and days off, with 13 out

"For quite some time, physicians have relied on Cordran® Lotion and Cordran® Cream to help treat a variety of skin conditions. With the launch of Cordran Ointment, physicians

Qudexy XR is a once-daily, broad-spectrum antiepileptic drug specifically engineered to deliver a smooth pharmacokinetic (PK) profile. It was approved by the U.S. Food and Drug Administration in

The company is focused on using its Verisome drug-delivery platform in the development of new unique intraocular eye-care therapeutics. IBI-10090, which employs the Verisome technology, has been designed

This recall is a precautionary measure based on the company’s investigation of visible particulate matter found in a small number of COUMADIN FOR INJECTION unreleased samples. Bristol-Myers Squibb

The product is marketed under the brand name ‘Breo Ellipta’ and is indicated for asthma patients aged 12 years and older. The sNDA is for approval of two